Testing EVER001 for kidney protein-loss diseases
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of FSGS, MCD, or IgAN by kidney biopsy
- Kidney function at least moderately preserved (eGFR ≥ 45)
- Significant protein in urine and low blood protein levels (for FSGS/MCD) or moderate-to-high protein in urine (for IgAN)
- No diabetes, active infections, or HIV/hepatitis B or C
- No current or untreated tuberculosis (TB)
- BMI below 35 if you have FSGS or MCD
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, MY008211A, for people with a type of kidney disease called IgA nephropathy. The goal is to see if it can reduce protein in the urine and help protect kidney function. You must have had a kidney biopsy confirming the diagnosis and be on stable standard care.
This trial tests an injected drug called BAT4406F for people with Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS), two types of kidney diseases that cause swelling and high protein in urine. It aims to see if the drug can help patients who have responded well to steroid therapy in the past.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.